Mark J. Sinnamon

834 citations
12 papers · 625 indexed · h-index 10

Impact in

Papers in

Mark J. Sinnamon

12 papers receiving 616 citations

Peers

Mark J. Sinnamon
Comparison fields: 5 of 66
  • Immunology and Allergy 60
  • Immunology 201
  • Cancer Research 137
  • Oncology 180
  • Molecular Biology 297
Replace Nisebita Sahu with:
Nisebita Sahu United States
Yingfu Liu China
Takashi Semba Japan
Muayad A. Zahalka Israel
Henrick Horita United States
Amanda Mikels‐Vigdal United States
Karen Morrison United Kingdom
Maozhen Tian United States
Tserenchunt Gansukh Germany
Mark J. Sinnamon relative to Nisebita Sahu United States Nisebita Sahu's profile →
Citations per field
00.5×2.5×
Nisebita Sahu · 1×
Citations per year

Countries citing papers authored by Mark J. Sinnamon

Since Specialization
Citations

This map shows the geographic impact of Mark J. Sinnamon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. Sinnamon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. Sinnamon more than expected).

Fields of papers citing papers by Mark J. Sinnamon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. Sinnamon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. Sinnamon. The network helps show where Mark J. Sinnamon may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark J. Sinnamon, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. Sinnamon Line = papers co-authored together Mark J. Sinnamon links everyone, so they are left out of the graph.

All Works

12 of 12 papers shown
#Work
1 201737
2 201437
3 20144
4 201370
5 20129
6 2011106
7 201169
8 201095
9 200833
10 200890
11 200714
12 200661

About Mark J. Sinnamon

Mark J. Sinnamon is a scholar working on Immunology and Allergy, Cancer Research, Oncology, Immunology and Genetics, having authored 12 papers that have together received 625 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (4 papers), PI3K/AKT/mTOR signaling in cancer (4 papers), Mast cells and histamine (3 papers), Protease and Inhibitor Mechanisms (3 papers), Cell Adhesion Molecules Research (3 papers), Colorectal Cancer Treatments and Studies (3 papers), Cancer, Hypoxia, and Metabolism (2 papers) and Melanoma and MAPK Pathways (2 papers). The work is most often cited by research in Immunology and Allergy (60 citations), Immunology (201 citations), Cancer Research (137 citations), Oncology (180 citations) and Molecular Biology (297 citations). Mark J. Sinnamon has collaborated with scholars based in United States, United Kingdom and Czechia. Frequent co-authors include Barbara Fingleton, Lynn M. Matrisian, Kathy J. Carter, Kenneth E. Hung, Jatin Roper, Eric S. Martin, Roberto Adachi, Richard L Stevens, Roderick T. Bronson and Erin M. Coffee. Their work appears in journals such as Molecular Cancer Research, Clinical Cancer Research, Cancer Letters, Circulation Research and Disease Models & Mechanisms.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026